Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilia Szostak

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Briefings in Functional Genomics|December 1, 2012
Translational control by 3'-UTR-binding proteinsEmilia Szostak, Fátima Gebauer
Methods in Molecular Biology (Clifton, N.J.)|April 30, 2011
Artificial tethering of Argonaute proteins for studying their role in translational repression of target mRNAsStephanie Eckhardt, Emilia Szostak, Zhaolin Yang, et al.
Nucleic Acids Research|April 11, 2018
Hrp48 and eIF3d contribute to msl-2 mRNA translational repressionEmilia Szostak, Marina García-Beyaert, Tanit Guitart, et al.
Lancet (London, England)|April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trialJosé Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Briefings in Functional Genomics|December 1, 2012
Translational control by 3'-UTR-binding proteinsEmilia Szostak, Fátima Gebauer
Methods in Molecular Biology (Clifton, N.J.)|April 30, 2011
Artificial tethering of Argonaute proteins for studying their role in translational repression of target mRNAsStephanie Eckhardt, Emilia Szostak, Zhaolin Yang, et al.
Nucleic Acids Research|April 11, 2018
Hrp48 and eIF3d contribute to msl-2 mRNA translational repressionEmilia Szostak, Marina García-Beyaert, Tanit Guitart, et al.
Lancet (London, England)|April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trialJosé Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
Pageof 1